Drugs / CXA-201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01445678 | Dec 2011 → Oct 2013 | — | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01345929 | Jun 2011 → Aug 2013 | pyelonephritis | Merck & Co., Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CXA-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01345929 ↗ |
| Route | Intravenous | “CXA-201 IV infusion (1500mg q8) for 7 days” NCT01345929 ↗ |